Filtered By:
Specialty: Infectious Diseases
Condition: SARS
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
US National Institutes of Health Prioritization of SARS-CoV-2 Variants
Emerg Infect Dis. 2023 Apr 13;29(5). doi: 10.3201/eid2905.221646. Online ahead of print.ABSTRACTSince late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic...
Source: Emerging Infectious Diseases - April 13, 2023 Category: Infectious Diseases Authors: Sam Turner Arghavan Alisoltani Debbie Bratt Liel Cohen-Lavi Bethany L Dearlove Christian Drosten Will M Fischer Ron A M Fouchier Ana Silvia Gonzalez-Reiche Lukasz Jaroszewski Zain Khalil Eric LeGresley Marc Johnson Terry C Jones Barbara M ühlemann David Source Type: research
Cutaneous reactions following COVID-19 vaccination assessed by dermatologists: a single-institutional study in Germany
CONCLUSIONS: It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.PMID:36892192 | DOI:10.1111/ddg.14987
Source: Herpes - March 9, 2023 Category: Infectious Diseases Authors: Rosi Wang Sonja Mathes Carla Claussen Tilo Biedermann Knut Brockow Source Type: research
Fauci: COVID-19 Is Here to Stay, but We Can Control It
(MedPage Today) -- Though it would be next to impossible to eradicate SARS-CoV-2, it is fully feasible to control it, said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), during a virtual event...
Source: MedPage Today Infectious Disease - April 29, 2022 Category: Infectious Diseases Source Type: news
NIH begins study of COVID-19 vaccination during pregnancy and postpartum
(NIH/National Institute of Allergy and Infectious Diseases) A new observational study has begun to evaluate the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum people. Researchers will measure the development and durability of antibodies against SARS-CoV-2, the virus that causes COVID-19, in people vaccinated during pregnancy or the first two postpartum months. Researchers also will assess vaccine safety and evaluate the transfer of vaccine-induced antibodies to infants across the placenta and through breast milk.
Source: EurekAlert! - Infectious and Emerging Diseases - June 23, 2021 Category: Infectious Diseases Source Type: news
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The therapeutic was developed by SAB Biotherapeutics, Inc. (Sioux Falls, South Dakota).
Source: EurekAlert! - Infectious and Emerging Diseases - April 21, 2021 Category: Infectious Diseases Source Type: news
Experimental antiviral for COVID-19 effective in hamster study
(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from NIH scientists. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2021 Category: Infectious Diseases Source Type: news
NIH experts discuss post-acute COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) Many people who have COVID-19 make a full recovery and return to their baseline state of health; however, some people have symptoms or other sequelae weeks or months after initial SARS-CoV-2 infection. These symptoms were the subject of the " Workshop on Post-acute Sequelae of COVID-19 " hosted on Dec. 2 and 4, 2020, by the National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with other institutes and centers of the NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - April 13, 2021 Category: Infectious Diseases Source Type: news
NIH experts discuss SARS-CoV-2 viral variants
(NIH/National Institute of Allergy and Infectious Diseases) The rise of significant variants of SARS-CoV-2 has attracted the attention of health and science experts worldwide. In an editorial published inJAMA, experts from the National Institute of Allergy and Infectious Diseases outline how these variants have arisen, concerns about whether vaccines currently authorized for use will continue to protect against new variants, and the need for a global approach to fighting SARS-CoV-2 as it spreads and acquires additional mutations.
Source: EurekAlert! - Infectious and Emerging Diseases - February 12, 2021 Category: Infectious Diseases Source Type: news
Study of coronavirus infection & multisystem inflammatory syndrome in children begins
(NIH/National Institute of Allergy and Infectious Diseases) An observational study has launched to evaluate the short- and long-term health outcomes of SARS-CoV-2 infection in children, including multisystem inflammatory syndrome in children, and to characterize the immunologic pathways associated with different disease presentations and outcomes. SARS-CoV-2 is the virus that causes COVID-19. The study, called the Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM), will enroll at least 250 children and young adults ages 20 years or younger.
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news
NIH trial testing hyperimmune intravenous immunoglobulin and remdesivir to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
Source: EurekAlert! - Infectious and Emerging Diseases - October 8, 2020 Category: Infectious Diseases Source Type: news
Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19 disease.
Source: EurekAlert! - Infectious and Emerging Diseases - September 30, 2020 Category: Infectious Diseases Source Type: news
NIH trial to test antibodies and other therapeutics for mild, moderate COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are working with clinical sites to identify potential patient volunteers currently infected with SARS-CoV-2, the virus which causes COVID-19, who have mild to moderate disease not requiring hospitalization.
Source: EurekAlert! - Infectious and Emerging Diseases - August 4, 2020 Category: Infectious Diseases Source Type: news
